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In 1990, 215 patients with operable breast cancer were entered into a prospective study of the prognostic significance of five
biochemical markers and 15 other factors (pathological/chronological/patient). After a median follow-up of 6.6 years, there
were 77 recurrences and 77 deaths (59 breast cancer-related). By univariate analysis, patient outcome related significantly to
13 factors. By multivariate analysis, the most important of nine independent factors were: number of nodes involved, steroid
receptors (for oestrogen or progestogen), age, clinical or pathological tumour size and grade. Receptors and grade exerted
their influence only in the first 3 years. Progestogen receptors (immunohistochemical) and oestrogen receptors (biochemical)
were of similar prognostic significance. The two receptors were correlated (r =+0.50, P=0.001) and displaced each other from
the analytical model but some evidence for the additivity of their prognostic values was seen when their levels were
discordant.
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A wide variety of clinical, pathological and biochemical factors are
of value in assessing prognosis and therefore in influencing the
management of patients with operable breast cancer (Stoll, 1992).
In 1990, a prospective trial examined four biochemical factors of
reported prognostic value, in a series of consecutive patients in
whom sufficient tumour was available analysis. After a median
follow-up of 3 years, data were analysed and the findings reported
(Hawkins et al, 1996).
The data have now been re-analysed at a median follow-up of
6.6 years with inclusion of a fifth biochemical marker and a Prog-
nostic Index has been derived from the key, important influential
factors.
METHODS
Details of the patients entered into the study and the methods
employed have been reported previously (Hawkins et al, 1996).
Patients
All women presenting between March 1990 and September 1991 at
the Edinburgh Breast Clinic with a unilateral, operable tumour,
containing sufficient tissue with 410% cancer cells to permit
performance of four biochemical analyses, were included in this
study.
Originally 215 patients (from approximately 650 newly diagnosed
breast cancers during this period) fulfilled these criteria. One patient
had previously undergone surgery for an invasive cancer so this
patient was excluded, leaving 214 patients for analysis. One hundred
and seventy-two patients received endocrine therapy (167 adjuvant,
five neoadjuvant), 37 chemotherapy (33 adjuvant, four neoadjuvant)
and seven had no adjuvant systemic therapy. The number of nodes
involved (no. nodes +) was known in 190 out of 214 patients from
either node sampling or clearance, both of which procedures
provide adequate information (Steele et al, 1985).
The median age at presentation was 55 years (n=214). Median
follow-up is now 6.6 years (range 5.3 – 7.7).
Tumour histopathology
Tumour (T) histopathology was reviewed by one of us (M McIn-
tyre) for pathological size, tumour grade and histopathological
type. Histological grade was assessed using the Bloom and Richard-
son (1957) system as modified by Elston and Ellis (1991).
Histopathological type was classified as previously described
(Hawkins et al, 1996).
Determination of the biochemical markers
The methods for determination of oestrogen receptors (ER) and
epidermal growth factor receptors (EGFR), cyclic adenosine mono-
phosphate-binding proteins (cAMP-b), cathepsin D (Cath D) and
protein concentration in cytosol or membranes have been reported
in detail previously (Hawkins et al, 1996).
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Determination of progestogen receptor (PgR) protein
Paraffin blocks, derived from the portion of the biopsy originally
used for the assay of the four biochemical markers, were sent to
the University of Birmingham. Sections were cut, incubated over-
night with a 1 : 4 dilution of 0.1 mg ml71 anti-PgR rat
monoclonal antibody (Abbott Laboratories) and stained for PgR
by a modification of the procedure reported by Soomro and
Shousha (1990).
Stained sections were scored, over the whole viable invasive
tumour area, for both proportion of cells exhibiting nuclear stain-
ing (0 – 100%) and average staining intensity (0, 1, 2, 3+) in
Edinburgh (M McIntyre). A ‘histoscore’ ranging from 0 – 300,
was calculated.
Of the 214 tumour blocks, 204 were assessable for PgR.
Combination of factors in prognostic indices
For 177 patients, data were available for the calculation of two
prognostic indices.
One well-established index (Miller et al, 2000), the Nottingham
Prognostic Index score (NPI), was calculated according to Hay-
bittle et al (1982).
To incorporate the influence of steroid receptor activity, into a
prognostic index, receptor levels were scored into four categories,
as used by Leake et al (2000). These were:
‘Receptor-negative’ ER 510 PgR=0 score=+1
‘Receptor-poor/low’ ER=10 – 99 PgR=1 – 99 score=0
‘Receptor-moderate’ one R 4100, other R 5100 score=71
‘Receptor-rich’ both R 4100 score=72
A receptor-modifed prognostic index was then calculated. In
calculating a ‘Receptor-modified NPI’, no attempt was made
to assess the optimal weighting for each factor. Instead, we arbi-
trarily allowed receptor status (values 72, 71, 0 and +1),
which in our data, appears to have approximately the same
level of prognostic influence as tumour grade (values 1, 2
and 3), to reduce the NPI by a maximum of two units (high
R levels=improving prognosis) or increase it by one unit (R-
negative=worsening prognosis).
Statistical analysis
All continuous variables were entered into the analysis without
categorisation or use of cut-offs.
For graphical presentation, the data were divided into quartiles
(tumour size, ER, age – Figure 2) or categories selected on the
basis of prior analyses (number of positive nodes – Figure 2,
PgR histoscore – Figure 3) or experience (ER – Figure 3) and
Kaplan – Meier estimates were used to provide survival curves.
Where hazard ratios have been used to indicate the magnitude
of a factor’s influence, these have been calculated for arbitrarily
selected, significant increments (doubling of R concentration,
decade increases in age, increase in pathological size by 1 cm,
tumour grade by one unit, soluble protein concentration by
1 mg ml71) or categories selected on the basis of preliminary
analysis (number of positive nodes).
The inter-relationships between variables were examined by
calculation of Spearman’s rank correlation coefficients.
The associations of the potential prognostic factors with time to
recurrence, disease-free survival and survival were investigated
using Cox’s proportional hazards models. In these analyses, vari-
ables with a skewed distribution (ER, PgR, Cath D and EGFR)
were log-transformed. Parameters determined at presentation or
surgery but influencing treatment (type of surgery, type of systemic
therapy and radiotherapy) were excluded from multivariate
analyses.
All prognostic variables were included singly in the models to
assess their univariate association with outcome variables (Table
1). Variables showing a statistically significant association with at
least one outcome variable were then considered in multivariate
analyses with allowance for possible time-dependency in the effect
of variables on outcome (Table 2). For each significant variable in
preliminary analysis, a new, time-dependent covariate was gener-
ated to allow the prognostic effect to differ between ‘early’ (first
3 years) and ‘later’ (43 years) time-periods. A model containing
all ‘significant’ variables and their corresponding time-dependent
co-variates was then fitted, with a stepwise removal of all non-
significant (P40.05) time-dependent variables. The final model
contains a mixture of variables, some of which showed a statisti-
cally significant difference between their ‘early’ and ‘later’ effects
and others which show an overall significant effect, but no time-
dependency.
Cox’s proportional hazards models were used to test whether
modification of the NPI to include the influence of steroid recep-
tors improved the relationship between the index and survival.
RESULTS
Patient outcome
Seventy-seven (36%) recurrences and 77 (36%) deaths occurred
during follow-up. Forty-seven patients had distant recurrences, 11
loco-regional recurrence only and 19 both. Fifty-nine (77%) deaths
were breast cancer-related, the remainder (18) being largely of
cardiovascular origin. One hundred and seventy-seven patients
were alive after 3 years and available for further analysis of the post
3-year period; 137 were alive at latest follow-up.
Associations between variables
Significant associations existed between the prognostic variables
(see Table 1 in Hawkins et al, 1996). Of the newer variables,
PgR (any nuclear staining) was detected in 162 out of 204 tumours
available for assay. Correlation between PgR and ER levels was
highly significant (P50.001) but moderate (Spearman’s rank
correlation coefficient, r=+0.50) and is illustrated in Figure 1.
PgR level was significantly inversely related to EGFR activity
(r=70.28, P=0.001) and tumour size (clinical, P=0.002, r=70.21
and pathological P=0.013, r=70.18).
Number of positive nodes correlated with clinical node status
(r=+0.37, P50.001), T stage (r=+0.28, P50.001), clinical T size
C
lin
ic
al
300
100
10
0
Pg
R 
(sc
ore
)
0                              10                            100                     1000
ER (fmol mg–1 protein)
Figure 1 The relationship between ER measured by biochemistry and
PgR detected by immunohistochemical staining in 204 patients with oper-
able breast cancer. Spearman’s Rank correlation coefficient=+0.50,
P50.001.
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(r=+0.32, P50.001) and pathological T size (r=+0.24, P=0.001), T
grade (r=+0.16, P=0.025), histopathological T type (r=+0.14,
P=0.04), tissue weight (r=+0.26, P=0.001) and Cath D activity
(r=+0.15, P=0.026).
Relationship of variables to outcome by univariate analysis
Thirteen variables were significantly related to at least one outcome
measure (Table 1).
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Figure 2 Kaplan – Meier curves for overall survival in 214 patients with operable breast cancer, after division of the patients into quartiles (for Path T size,
these were 51.5, 51.5 –52.2, 52.2 – 3.0 and 43.0 cm; for ER 511, 11 – 63, 64 – 164 and 4164 fmol mg71 protein and for age, 549, 549 –455,
56 – 63 and 463 years) or four groups (Nodes involved 0, 1, 2 and 43).
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Figure 3 Comparison of the relationships between ER, determined by biochemistry, and PgR, determined by immunohistochemistry, to disease-free
survival, using optimised levels.
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For local recurrence, the most important factors were number of
positive nodes, T grade and ER activity. Factors related to distant
recurrence, disease-free survival and overall survival were very simi-
lar except that for overall survival, age was a highly significant
factor (P=0.005).
Four key factors influenced outcome, number of positive nodes ,
pathological T size, ER concentration and age and these were
divided into quartiles (for nodes involved, four groups were 0, 1,
2 and 43 ); their effect is illustrated as Kaplan – Meier survival
curves in Figure 2. The effect of age related specifically to a poorer
survival for the oldest patients dying from all causes (age 463
years) or from breast cancer only (not shown).
Relationship of variables to outcome by multivariate
analysis
The important factors (Table 2) were number of positive nodes,
steroid receptors, tumour size and grade, patient age and soluble
protein concentration.
The effects of receptors and grade were, however, apparent only
during the first 3 years of follow-up.
Comparative importance of ER and PgR as prognostic
factors
Oestregen receptor and PgR activities were the only ‘biochemical’
activities confirmed to be of prognostic significance. The prognos-
tic data obtained from the two measurements are virtually
equivalent. This is illustrated in the survival curves in Figure 3:
ER was divided according to levels found useful through experience
(55=‘negative’, 5 – 19=‘poor’, 20 – 99=‘moderate’, 4100=‘rich’,
fmol mg71 protein) whilst for PgR, the cut-offs (0, 1 – 39, 40 –
160 and 4160 histoscore) were selected retrospectively to provide
the best separation between survival curves.
There were 33 patients in whom there was some discrepancy
between the results of ER and PgR assays (Table 3). Of these,
patients with a tumour rich in one receptor (either ER or PgR)
had a better outcome than those with tumours rich in neither
receptor.
Combination of prognostic factors as prognostic indices
The Nottingham Prognostic Index (NPI) was calculated for the 177
patients with sufficient data. Increasing levels of the NPI were asso-
ciated with decreasing percentages of patients surviving (from
death of any cause) at 3, 5 or 7 years as demonstrated in Table 4.
When the NPI was modifed to incorporate steroid receptor
levels, values ranged from 0.20 to 8.92. The relationship between
survival after 7 years and the new, modified index was better,
becoming more nearly linear (Figure 4). This modification
produced a statistically significant improvement in the fit
(w2=9.9, P=0.002).
DISCUSSION
Aims of study
The original aim of this study was to identify newer biochemical
markers of prognosis which might add to the value of ER (Knight
et al, 1977; Shek and Godolphin, 1989) to increase the ability to
predict outcome in operable breast cancer. However, epidermal
growth factor receptors, cathepsin D and cyclic AMP-binding
proteins were not related to outcome, by either univariate or
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Table 1 Relationship of variables to outcome in 214 patients with
operable breast cancer using Univariate Cox’s proportional hazards models
P values
Factor Any* Local* Distant* DFS Survival
No. nodes+ 50.0001 0.006 50.0001 0.0001 50.0001
log ER 50.0001 0.03 50.0001 0.0003 50.0001
log PgR 0.0003 0.07 0.0005 0.0005 0.0001
T grade 50.0001 0.004 50.0001 0.0007 0.002
T size clin 50.0001 0.35 50.0001 0.0005 0.002
T size path 50.0001 0.08 50.0001 0.0001 50.0001
Type surg 0.0023 0.87 0.0005 0.0099 0.0067
N Status 0.0045 0.11 0.0042 0.015 0.01
T Stage 0.0089 0.86 0.0039 0.03 0.20
Sol prot 0.022 0.06 0.07 0.017 0.016
RTX 0.032 0.36 0.031 0.036 0.057
Tissue wt 0.072 0.16 0.073 0.18 0.72
Memb Prot 0.094 0.89 0.04 0.24 0.22
Sys ther 0.10 0.07 0.052 0.087 0.18
log CathD 0.11 0.28 0.24 0.32 0.46
Hist type 0.28 0.38 0.28 0.45 0.65
log EGFR 0.29 0.25 0.37 0.60 0.57
Men Status 0.39 0.52 0.16 0.96 0.37
cAMP-b 0.58 0.87 0.54 0.88 0.92
Age 0.78 0.30 0.20 0.10 0.0048
*=risk of recurrence; DFS=disease-free survival; Sol prot and memb prot=soluble
and membrane protein concentrations; Type surg=type of surgery; N=node;
RTX=radiotherapy; wt=weight; sys ther=type of systemic therapy; Hist
type=histopathologcial tumour type.
}
}
}
Table 2 The relationship of prognostic variables to outcome in 214
women with operable primary breast cancer using an approach with
time-dependent covariates
Variable
Hazard
ratio
(95% confidence
intervals) P value
Survival
Nodes 0 1
1 – 2 1.68 (0.82, 3.41)
3+ 5.24 (3.02, 9.09) 50.001
NK 1.80 (0.89, 3.66)
Age (/decade) 1.49 (1.22, 1.82) 0.001
ER (/doubling) 0.65 (0.53, 0.79) 50.001
PgR – – NS
sol prot (/mg) 1.02 (1.00, 1.05) 0.02
Disease-free survival
Nodes 0 1
1 – 2 1.24 (0.66, 2.36)
3+ 4.53 (2.71, 7.55) 50.001
NK 1.89 (0.99, 3.59)
ER – – NS
PgR* (doubling)
early phase 0.52 (0.40, 0.68) 50.001
later phase 0.96 (0.72, 1.30) 0.80
Time to recurrence
Nodes 0 1
1 – 2 1.20 (0.58, 2.51)
3+ 4.03 (2.24, 7.25) 50.001
NK 1.58 (0.73, 3.41)
ER – – NS
PgR (/doubling) 0.71 (0.56, 0.89) 0.003
clin T size (/cm) 1.16 (1.01, 1.34) 0.03
Grade**
early phase 2.40 (1.33, 4.34) 0.004
later phase 0.82 (0.46, 1.47) 0.50
Factors listed are those showing a significant effect on outcome in either the whole
follow-up period or in at least one phase in preliminary analyses. Both steroid recep-
tors are listed for completeness but usually one receptor entered the model first,
eliminating the major influence of the other. *P=0.002 and **P=0.008 for differ-
ences between early and later periods. Models containing PgR are calculated from
the 204 patients in whom this was available. NK=not known.
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multivariate analysis. This may be due to a variety of factors
(Hawkins, 1993; Hawkins et al, 1996), the population studied,
which included mainly larger tumours (sufficient for four biochem-
ical analyses) and consisted of only one-third of all the patients
presenting to our Breast Clinic, or to intra-tumoural variations
(Barranco et al, 1994).
This re-analysis set out to determine the importance of the
various factors over a longer period and to determine if the key
prognostic factors had changed with time.
Factors influencing outcome
Three measures of outcome have been considered here: overall
survival, disease-free survival and time to recurrence. (The latter
relates more specifically to breast cancer than disease-free survival
which incorporates mortality unrelated to breast cancer.) Since
most of the factors studied are inter-related (e.g. T grade relates
to age, T stage, clinical T size, pathological T size, node status, T
histopathological type, log ER, and number of positive nodes), then
the loss of small numbers of patients from a group of 200 or so
(due to missing values) may cause some surprising changes to
the factors emerging as ‘significant’ in the final model derived by
multivariate analysis. In order to minimise this influence, the
analyses were iterated to obtain finally the maximum possible
number of patients for whom the key, significant variables were
available.
For overall survival, the number of nodes involved at either node
sampling or node clearance was the most important factor; it
displaced clinical node status from the statistical model. Patients
with three or more nodes involved had an increased risk of death
of over five-fold compared to patients with no nodes involved. ER
activity also significantly influenced survival with a decrease in
hazard ratio of 0.65 for every doubling of ER level, displacing
PgR from the model for this outcome. Age influenced risk of death
from all causes (increase in hazard ratio of 1.49 per decade of
ageing) and also death due to breast cancer. This is in line with
the earlier observations of Adami et al (1985). Soluble protein
concentration was associated with a slight but significant increase
risk of death, as noted by Soreide et al (1991); this may be because
it accurately reflects tumour cellularity (Hawkins et al, 1988).
For disease-free survival, number of nodes involved was the key
factor with PgR being the only other significant factor. The effect
of PgR was time-dependent. This time-dependence of the effect
of steroid receptors was apparent, though not statistically signifi-
cant, in all measures of outcome (overall survival – ER, disease-
free survival and time to recurrence – PgR).
For time to recurrence, the key factors were number of nodes
involved, PgR, tumour grade and clinical size (Table 2).
However, the effect of grade was time-dependent, having its
influence only in the early period.
Role of steroid receptors
Steroid receptors were of prognostic significance only within the
first 3 years of follow-up. The time-dependency has been noted
previously (Saez et al, 1983; Pichon et al, 1996). It may explain
why, in studies of patients with large, operable tumours treated
by neoadjuvant therapy, short-term response but not long-term
survival related strongly to ER level (Anderson et al, 1989; cf.
Cameron et al, 1997).
Although 172 of our patients received adjuvant endocrine ther-
apy, a similar trend for improving outcome with increasing ER
level was apparent in the remaining 43 patients who did not receive
endocrine treatment (data not shown); the influence of receptors
may thus be independent of the use of endocrine therapy.
Both ER and PgR were related to outcome with one often
displacing the other in different multivariate analyses. The value
of immunoreactive PgR protein, confirms earlier findings (Baker
et al, 1995) but is in contrast to our earlier studies (Hawkins et
al, 1987; Watson et al, 1987) using radioligand-binding assay,
which may be less reliable for detecting PgR protein. There was
some evidence in the current study for an additivity of the prog-
nostic values of the two receptors: patients with a ‘receptor-rich’
tumour (4100 ‘units’ by either assay) had a good prognosis.
This ‘additivity’ may relate to (1) the benefits of conducting the
‘receptor’ assay twice (i.e. ‘in duplicate’), (2) the possibility that
two different modes of assay complement each other or (3) that
each protein has a unique prognostic value.
The findings presented here are broadly in line with those of
other studies, though slight differences from some studies may
relate to the use of receptors as a discontinuous variable with selec-
tion of arbitrary cut-offs, or to pooling of data from several centres
with different levels of quality control.
Combination of factors in a prognostic index
For clinical purposes, it is useful to be able to combine key prog-
nostic factors into a single ‘prognostic index’. The most
commonly used, the Nottingham prognostic Index (NPI), incor-
porates tumour grade, pathological size and number of nodes
involved. This index was of prognostic value in the present study
(Table 4). However, the discriminatory power of the NPI was
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Table 3 Outcome in individual patients with discordant ER and PgR
activities
Patient PgR ER Outcome*
(a) PgR negative, ER-significant (n=24)
a 0 23 –
b 0 24 s+d
c 0 27 s
d 0 30 –
e 0 32 –
f 0 47 –
g 0 48 l+s+d
h 0 50 l+s+d
i 0 58 –
j 0 58 s+d
k 0 76 s+d
l 0 78 d (not Br Ca)
m 0 82 s+d
n 0 92 s+d
ER-rich 4100
o 0 121 d (not Br Ca)
p 0 156 –
q 0 164 d (not Br Ca)
r 0 187 –
s 0 213 –
t 0 278 1
u 0 302 –
v 0 369 –
w 0 387 –
x 0 467 –
(b) PgR-positive, ER-poor/negative (n=9)
pa 30 19 s+d
pb 40 6 d (not Br Ca)
pc 40 11 s+d
PgR rich 4100
pd 110 16 –
pe 110 17 –
pf 140 18 –
pg 200 16 –
ph 230 3 –
pi 260 14 –
* – =alive+well; s=systemic disease, l=local disease; d=dead from Br Ca (=breast
cancer). ER=fmol mg71 protein, PgR=histoscore.
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only slightly better than that found using numbers of nodes
involved alone (data not shown). This could be due to our
patients with 43 nodes positive having a much poorer survival
than those with 1 – 2 nodes involved (cf. patients with 1 – 3 nodes
positive being pooled in the NPI). The NPI omits any prognostic
contribution from steroid receptor activity. Modification of the
NPI by incorporating a ‘correction’ for steroid receptor levels
significantly improved the relationship to survival at 7 years
(Figure 4).
All prognostic indices reflect estimates of a probability of
outcome for which there can be no certainty. In this series, one
patient, with a grade-III, receptor-negative tumour of 9.6 cm
and 12 nodes involved at presentation, was alive and well when
last seen.
Conclusion
Factors significantly influencing prognosis include number of
nodes involved on sampling or clearance, age, tumour size, steroid
receptor activity and tumour grade. The effects of steroid receptors
and grade are time-dependent. ER and PgR are of equivalent value.
Combination of number of involved nodes, tumour grade, tumour
size and steroid receptors in a prognostic index provides a more
accurate assessment of prognosis for most patients than the NPI
alone.
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Figure 4 The relationship between the percentage of patients surviving
from breast cancer and (a) the Nottingham Prognostic Index (dotted line)
and (b) a Steroid receptor-modified NP Index (solid line) for 177 patients
with operable breast cancer. Percentage survival values are plotted at the
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2.4 – 3.4.
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